Abstract
During an epidemic of group B meningococcal infection mean values obtained in 96 consecutively affected children showed a reduction in classical pathway function (CH50), normal alternate pathway function (AP50), C4 and factor B levels, and raised C3 levels. CH50, C3 and Factor B were however significantly lower in those children who had a rapid onset of illness, were in shock, had signs of septicaemia, had extensive skin purpura, or who died. The presence of detectable meningococcal antigen by Counter Immuno Electrophoresis (CIE) and laboratory evidence of Disseminated Intravascular Coagulation (DIC) also correlated with lower complement levels. The significant reduction in CH50 and Factor B in the more severely affected patients suggests that activation of both classical and alternate pathways occurs in group B meningococcal infection.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bjorvatn B., Bjertnaes L., Fadnes H. O., Flaegstad T., Gutteberg T. J., Kristiansen B. E., Pape J., Rekvig O. P., Osterud B., Aanderud L. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Br Med J (Clin Res Ed) 1984 Feb 11;288(6415):439–441. doi: 10.1136/bmj.288.6415.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bokisch V. A., Top F. H., Jr, Russell P. K., Dixon F. J., Müller-Eberhard H. J. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med. 1973 Nov 8;289(19):996–1000. doi: 10.1056/NEJM197311082891902. [DOI] [PubMed] [Google Scholar]
- Edwards E. A. Immunologic investigations of meningococcal disease. I. Group-specific Neisseria meningitidis antigens present in the serum of patients with fulminant meningococcemia. J Immunol. 1971 Feb;106(2):314–317. [PubMed] [Google Scholar]
- Ellison R. T., 3rd, Kohler P. F., Curd J. G., Judson F. N., Reller L. B. Prevalence of congenital or acquired complement deficiency in patients with sporadic meningocococcal disease. N Engl J Med. 1983 Apr 21;308(16):913–916. doi: 10.1056/NEJM198304213081601. [DOI] [PubMed] [Google Scholar]
- Fearon D. T., Ruddy S., Schur P. H., McCabe W. R. Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N Engl J Med. 1975 May 1;292(18):937–940. doi: 10.1056/NEJM197505012921802. [DOI] [PubMed] [Google Scholar]
- Fireman P., Zuchowski D. A., Taylor P. M. Development of human complement system. J Immunol. 1969 Jul;103(1):25–31. [PubMed] [Google Scholar]
- Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–1326. doi: 10.1084/jem.129.6.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Greenwood B. M., Onyewotu I. I., Whittle H. C. Complement and meningococcal infection. Br Med J. 1976 Apr 3;1(6013):797–799. doi: 10.1136/bmj.1.6013.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Haller L., Zubler R. H., Lambert P. H. Plasma levels of complement components and complement haemolytic activity in protein-energy malnutrition. Clin Exp Immunol. 1978 Nov;34(2):248–252. [PMC free article] [PubMed] [Google Scholar]
- Hoffman T. A., Edwards E. A. Group-specific polysaccharide antigen and humoral antibody response in disease due to Neisseria meningitidis. J Infect Dis. 1972 Dec;126(6):636–644. doi: 10.1093/infdis/126.6.636. [DOI] [PubMed] [Google Scholar]
- Ribeiro M. A., Fava Netto C., dos Santos M. C. Determinaço do complemento hemolítico total e do compenente c3 em pacientes de meningite meningococica. Rev Inst Med Trop Sao Paulo. 1981 Sep-Oct;23(5):185–187. [PubMed] [Google Scholar]
- Tubbs H. R. Endotoxin in meningococcal infections. Arch Dis Child. 1980 Oct;55(10):808–810. doi: 10.1136/adc.55.10.808. [DOI] [PMC free article] [PubMed] [Google Scholar]